Phase II study of sorafenib/bevacizumab as salvage therapy in patients with metastatic colorectal cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00826540?term=N054C&rank=1

2. Intervention

   Sorafenib/bevacizumab

3. Additional Topic(s)

   Combination antineoplastic chemotherapy

4. Resource Description

   Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with bevacizumab may kill more tumor cells. This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with metastatic colorectal cancer.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   colorectal cancer

8. Study Population

   Men and women 18 years and older with stage IV colorectal cancer

9. Funded by

   North Central Cancer Treatment Group

10. Phase

    Phase 2 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource